Go to the Globe and Mail homepage

Jump to main navigationJump to main content

In this Oct. 10, 2008 file photo illustration, Johnson & Johnson products are shown in Philadelphia. (Matt Rourke/AP)
In this Oct. 10, 2008 file photo illustration, Johnson & Johnson products are shown in Philadelphia. (Matt Rourke/AP)

J&J beats forecast, takes new charge for recalled hips Add to ...

Johnson & Johnson reported better-than-expected fourth-quarter earnings on Tuesday, fuelled by rebounding sales of prescription drugs and demand for its medical devices, but took another big special charge for its recalled artificial hips.

The diversified health care company on Tuesday said it earned $2.6-billion (U.S.), or 91 cents per share. That compared with $218-million, or 8 cents per share, in the year-ago period when the company took charges of more than $3-billion, including $800-million for medical costs related to recalls of defective “metal-on-metal” hip replacement devices made by its DePuy Orthopedics unit.

Excluding special items, J&J earned $1.19 per share. Analysts, on average, expected $1.17 per share.

Global revenue rose 8 per cent to $17.56-billion, below Wall Street expectations of $17.7-billion.

Follow us on Twitter: @GlobeInvestor

 
Security Price Change
JNJ-N Johnson & Johnson 102.30 0.34
0.333 %
Add to watchlist
Live Discussion of JNJ on StockTwits
More Discussion on JNJ-N

Topics:

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories